Overview of TransAct

Quick Facts

Property	Description
Active ingredient	Flurbiprofen
Form	Transdermal Therapeutic System (Patch)
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Relief of localized pain and inflammation
Origin	Synthetic (Propionic acid derivative)

The Identity and Classification of the TransAct Preparation

TransAct is a medical preparation whose active substance is flurbiprofen, which belongs to the widely recognized Nonsteroidal Anti-inflammatory Drug (NSAID) class. Flurbiprofen is a synthetic compound within the propionic acid derivative group, chemically distinct from older analgesics. The substance is recognized for its efficacy as an antirheumatic and analgesic agent, confirming its core role in mitigating physical discomfort and inflammation.

Composition, Form, and Delivery Type

The preparation is provided as a specialized Transdermal Therapeutic System, commonly known as a patch, designed for a topical route of administration. This dosage form is a key distinguishing feature of the product. The patch contains the active ingredient flurbiprofen embedded within a polymer matrix that serves as the base. Unlike oral forms of flurbiprofen, this transdermal delivery system is specifically formulated for targeted action and is clinically positioned to address localized musculoskeletal discomfort, such as strain in a joint.

Fundamental Action and General Benefit

Its general purpose is to deliver a reliable localized anti-inflammatory and analgesic effect. It achieves this by using flurbiprofen to temporarily reduce the production of prostaglandins, which are key chemical mediators of pain and swelling. The inherent design of the patch ensures that the drug concentrates in the affected tissue, providing the benefit of targeting localized pain and inflammation where it originates.

What side effects are possible with TransAct?

Possible Side Effects and Safety Information

The overall safety profile of the flurbiprofen transdermal patch is officially documented by regulatory authorities, with adverse reactions generally categorized by the affected system and frequency.

Adverse Reactions and Systemic Potential

The most common adverse reactions are localized to the application site, reflecting the transdermal delivery. These typically involve skin reactions such as itching (pruritus), redness (erythema), numbness, and a tingling sensation (paresthesia). While low compared to oral formulations, the potential for systemic side effects cannot be excluded, particularly with prolonged use.

As the active substance, flurbiprofen, belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, systemic effects documented in official labeling include reactions within the Gastrointestinal (e.g., nausea, epigastric pain) and Nervous System (e.g., headache, slight dizziness) categories.

Serious Adverse Reactions and Safety Constraints

The medicine is associated with serious, class-wide NSAID risks. Regulatory documents highlight the potential for serious gastrointestinal adverse events (e.g., bleeding, ulceration) and serious cardiovascular thrombotic events (e.g., myocardial infarction, stroke), risks which may increase with the duration of use. Anaphylactic/anaphylactoid systemic reactions are also officially noted as a potential safety concern.

Specific constraints apply: the preparation is contraindicated for individuals with a history of NSAID-induced hypersensitivity (such as bronchospasm) or active peptic ulcer/haemorrhage. Furthermore, due to the drug class risk, use is formally restricted beginning at 30 weeks of gestation in pregnancy, and older adults are advised to be at greater risk for serious gastrointestinal events. Monitoring of blood counts and hepatic/renal function is indicated for prolonged use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope and Manifestations

While the risk of systemic overdose is low due to the transdermal nature of TransAct, severe systemic symptoms are officially documented for excessive exposure. Manifestations noted in regulatory sources for Flurbiprofen overdose primarily involve the Central Nervous System (CNS) and the Gastrointestinal (GI) system. Documented presentations include nausea, vomiting, stomach pain, dizziness, and somnolence, potentially progressing in severe cases to changes in consciousness or coma. Serious outcomes listed include potentially fatal GI bleeding, ulceration, and perforation, as well as acute renal failure. Elderly patients and those with underlying renal or hepatic impairment are noted to be at a higher risk for these severe events.

Immediate Response and Emergency Action

Regulatory authorities mandate specific actions upon suspected overexposure. The first step is to immediately remove the patch and wash the skin with water. Due to the risk of life-threatening events, such as collapse, difficulty breathing, or loss of consciousness, individuals must contact emergency services or a hospital immediately.

Treatment is strictly symptomatic and supportive, as official labeling confirms that no specific antidote is known for Flurbiprofen overdose. Monitoring of vital signs and renal function is a required component of the hospital management protocol following severe overexposure.

Therapeutic Uses of TransAct

What TransAct Treats: Main Uses and Benefits

This patch is generally used in situations involving certain distressing symptoms related to physical discomfort and applied across domains where additional symptomatic support is needed. Medications in this class are relevant for the local symptomatic and short-term treatment of pain in acute strains, sprains, or bruises.

It is primarily used for managing symptom clusters that may become intense or disruptive, such as localized pain, tenderness, and inflammation, which often accompany minor injuries or muscle overuse. The medication is commonly used when symptoms intensify and supportive relief is needed in contexts involving increased discomfort, such as tendinitis and ligament strain.

The medication is applied in addressing symptoms that interfere with daily functioning. It contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Localized Pain and Swelling

Regulatory References

European Clinical Trials Register

Eligibility and Restrictions for Use

The eligibility for using the TransAct (Flurbiprofen Transdermal Patch) is strictly defined by regulatory documents, primarily based on contraindications related to hypersensitivity and systemic risk from the Nonsteroidal Anti-inflammatory Drug (NSAID) class.

Eligibility Scope	Status	Regulatory Basis
Populations Contraindicated (Must Not Use)	Hypersensitivity: Individuals allergic to flurbiprofen, aspirin, or any other NSAID. Late Pregnancy: Women in the third trimester (around 20-30 weeks gestation and later). Surgery: Patients in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery. Severe Organ Failure: Severe heart, liver, or kidney failure.	Absolute prohibition due to risk of fetal harm, severe allergic reaction, or cardiovascular complication.
Age-Related Eligibility	Minimum Age: Not indicated for use in children under 12 years of age. Older Adults: Requires caution and monitoring due to increased risk of NSAID side effects (e.g., GI bleeding).	Safety and efficacy not established below age 12. Increased monitoring required for the elderly.
Condition-Specific Caution	Patients with a history of peptic ulceration, gastrointestinal haemorrhage, hypertension, heart failure, or mild to moderate renal/hepatic impairment. Lactation: Use not recommended as safety is not established.	Use is permitted, but requires caution due to potential for systemic effects from NSAID class absorption.

Official documents define who can and cannot use the medicine by formalizing absolute contraindications for specific high-risk groups and establishing age-related minimums. Eligibility is further structured by requiring caution and monitoring in populations with pre-existing conditions like organ dysfunction, which may be susceptible to systemic NSAID effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for TransAct, whose active ingredient is flurbiprofen, is based strictly on regulatory warnings regarding its systemic absorption as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Documented Pharmacological Constraints

Classification	Official Regulatory Constraint
Contraindicated Combinations	Co-administration with New Quinolone Antibiotics (e.g., Lomefloxacin, Norfloxacin) is formally prohibited due to the documented risk of inducing convulsions.
Pharmacodynamic Risk	Combining with other NSAIDs or analgesic doses of salicylates is officially discouraged due to the additive risk of serious gastrointestinal events, such as bleeding or ulceration.
PK Exposure Alteration	Flurbiprofen may inhibit the renal clearance of Lithium or Methotrexate, resulting in increased plasma concentrations of these co-administered drugs. Co-administration with CYP2C9 Inhibitors (e.g., Fluconazole) increases flurbiprofen systemic exposure.
Bleeding Risk Reinforcement	Concomitant use with Anticoagulants (e.g., Warfarin), SSRIs/SNRIs, and the herbal product Ginkgo carries an officially documented, synergistic increase in the risk of bleeding.

Population and Substance Notes

The interaction with ACE Inhibitors and ARBs in the elderly or those with impaired renal function is officially noted for the risk of deterioration of renal function. Ingestion of alcohol is associated with an additive increase in the risk of gastrointestinal reactions.

Mechanism of Action

How TransAct Works

Enzyme Inhibition: Blocking Prostaglandin Synthesis

The mechanism of action for the active ingredient, flurbiprofen, is defined by its ability to modulate specific biological pathways involved in prostaglandin synthesis. The mechanism proceeds from a molecular interaction to physiological adjustments in the local tissue.

The drug acts as a non-selective, reversible inhibitor of the Cyclooxygenase ( COX) enzyme system, which includes both the COX-1 and COX-2 isoforms. By occupying the enzyme's active site, flurbiprofen prevents the critical first step—the conversion of arachidonic acid into various prostaglandins. This molecular interference initiates the mechanistic cascade.

Physiological Outcome: Modulating Vascular and Sensory Signals

The suppression of prostaglandin synthesis directly leads to two linked physiological consequences in the peripheral tissue. First, reduced prostaglandin levels decrease the degree of vasodilation and capillary permeability. Second, the absence of these mediators functionally raises the activation threshold of peripheral nociceptors (sensory nerve endings), which affects the transmission of peripheral signals.

Dosage and Administration Information

TransAct is administered using the topical route via a dermal patch and is for use only in adults. The official instructions define the precise application steps, dosing frequency, and maximum duration of use.

Official Dosing and Frequency

Dosing: Apply one patch to the affected area. Each patch contains 35 mg of flurbiprofen.
Frequency: A fresh patch must be applied to the site every 12 hours, resulting in a twice-daily regimen. The patch should not be used for a period longer than 4 weeks.

Administration Procedure

Preparation: The site of application must be clean and dry before applying the patch.
Application: Remove the protective backing film from the patch. Apply the adhesive side directly to the skin over the affected area.
Special Condition: When applying the patch to highly mobile joints (e.g., the knee or elbow), it is advised to bend the joint before the application and then stretch the patch slightly around the joint while applying.

Missed Dose Guidance

If a dose is missed, apply the next patch as soon as it is remembered. Continue with the standard 12-hour dosing schedule thereafter. Do not apply two patches simultaneously to compensate for a forgotten application.

This procedural structure ensures a consistent, targeted delivery of the medicine through the skin, maintaining the official guidelines for patient use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for TransAct

This section provides an overview of the types of studies that have examined the flurbiprofen patch, detailing the populations and outcomes monitored by researchers. This summary does not offer clinical advice, dosing information, or personal medical predictions.

Evidence for Use in Acute Localized Injuries

The research examining the flurbiprofen patch was primarily conducted in trials for localized, sudden injuries—such as common sprains or muscle strains—which typically involves randomized controlled trials (RCTs). This design was studied for conditions associated with acute or disruptive episodes where symptoms are expected to resolve relatively quickly. Researchers monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes. When comparing the groups, studies reported patterns where the measured changes in pain intensity were different between the group using the active patch and the group using the placebo patch during the initial short-term observation period. However, since follow-up durations were limited to the acute phase of the injury, there is limited information for long-term outcomes or recovery patterns beyond the first two weeks.

Evidence for Use in Chronic Localized Joint Conditions

The flurbiprofen patch was evaluated in studies examining its use for persistent discomfort in joints, most commonly for knee osteoarthritis. This research examined conditions characterized by fluctuating or episodic manifestations of pain and stiffness. Researchers monitored patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. These observations was observed in over intermediate time intervals, typically ranging from two to four weeks. A key uncertainty in this area is that the follow-up durations were limited in most controlled comparisons. Additionally, comparative evidence is lacking against oral forms of non-steroidal anti-inflammatory drugs (NSAIDs).

What is Still Uncertain about TransAct Research

While studies help show what has been observed so far, the research landscape has distinct limitations and areas where certainty remains low. The high-quality, randomized evidence is focused on acute or short-term periods, meaning there is limited information for long-term outcomes regarding the sustained effects of symptom relief. Data for certain groups remain insufficient, including the pediatric population. Subgroup findings are also uncertain regarding patients with pre-existing comorbidities, reinforcing that results apply only to the populations studied. It is important to remember that research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References Osteoarthritis: care and management (NICE Guideline NG236)

Frequently Asked Questions (FAQ)

Common questions about TransAct (FAQ)

Q: Is TransAct considered a narcotic or a controlled substance?

According to the official product information, the active ingredient in TransAct is flurbiprofen, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a narcotic or a controlled substance within the major regulatory guidelines.

Q: Can TransAct be used for pain that is not related to a recent injury?

Regulatory documents indicate TransAct is used for the symptomatic relief of localized pain and inflammation. This includes conditions associated with soft tissue rheumatism, trauma (such as sprains), and osteoarthritis in joints.

Q: Does TransAct target the cause of the inflammation, or just mask the pain?

The mechanism is defined by its ability to modulate the body's inflammatory process. It achieves this by inhibiting the Cyclooxygenase (COX) enzyme system, which interferes with the production of prostaglandins—the chemical mediators associated with pain and swelling.

Q: Is it possible for a topical patch like TransAct to cause stomach issues?

The possibility of systemic side effects cannot be entirely excluded, particularly with prolonged use. Official labeling includes reactions within the Gastrointestinal category such as nausea and epigastric pain. The potential for serious gastrointestinal events is officially noted as a class-wide NSAID risk.

Q: Are there any serious or rare side effects associated with the flurbiprofen in TransAct patches?

Official safety information notes the potential for serious class-wide NSAID risks. These include serious gastrointestinal events (like bleeding or ulceration), cardiovascular thrombotic events (such as heart attack or stroke), and serious allergic reactions (anaphylaxis).

Q: Does TransAct interact with common blood pressure medications?

Official documents specifically note a constraint when combining TransAct with ACE Inhibitors or ARBs (Angiotensin II Receptor Blockers). This is due to a potential risk of deterioration of renal function, particularly in older adults or those with pre-existing kidney issues.

Q: Is TransAct safe for use by older adults or the elderly population?

Older adults are officially noted to be at greater risk for serious class-wide NSAID events, such as gastrointestinal bleeding or ulceration. Due to this increased risk, regulatory documents state that this population requires caution and monitoring of blood counts and hepatic/renal function during prolonged use.

Q: Is there a maximum number of days or weeks that TransAct can be used continuously?

Official product information states that the medicine is not indicated for continuous use for more than four weeks. This restriction is in place because insufficient safety data is available for continuous use beyond that duration in regulatory documents.

Q: Is it possible to become dependent on TransAct patches for pain relief?

Regulatory documents categorize the risks of TransAct based on the Nonsteroidal Anti-inflammatory Drug (NSAID) class effects, such as cardiovascular or gastrointestinal risks. Dependence or addiction is not listed as a potential safety concern for this medicine.

Q: Does the use of TransAct affect blood tests or lab results?

Systemic effects documented in official labeling include the potential for elevated transaminase levels (which relates to liver function). For this reason, regulatory documents state that monitoring of blood counts and hepatic/renal function is indicated for prolonged use.

Q: Does TransAct come in any form other than a patch?

The TransAct preparation itself is officially defined as a specialized Transdermal Therapeutic System, commonly known as a patch. This specific dosage form is designed for topical, localized administration.

Q: Is TransAct the same as other flurbiprofen products?

TransAct is defined by its transdermal delivery system. This patch formulation is specifically developed for targeted, localized action, which distinguishes it from other flurbiprofen products that may be available in oral or other forms.

Q: What should a user do if they accidentally apply two TransAct patches at the same time?

Official instructions explicitly advise against applying two patches simultaneously. The documented symptoms of overdose for the active substance (flurbiprofen) include changes in consciousness, difficulty breathing, and severe abdominal discomfort.

Q: Why is TransAct not recommended for use by children under a certain age?

Regulatory documents state that TransAct is not indicated for use in children under 12 years of age. This is because the safety and efficacy of the preparation have not been established in this younger population.

Q: Have studies examined the long-term safety of using TransAct patches for several months?

Research reviews indicate that the available high-quality, randomized evidence primarily focuses on acute or short-term periods (up to a few weeks). This means there is limited information in controlled settings for long-term outcomes regarding the sustained effects of symptom relief beyond the short term.

Q: What is the difference between the ingredient in TransAct and the active ingredients in non-NSAID topical patches?

TransAct contains the active ingredient flurbiprofen, a Nonsteroidal Anti-inflammatory Drug (NSAID). NSAIDs work by inhibiting the COX enzyme system to reduce prostaglandins, a mechanism that distinguishes them from non-NSAID topical agents which rely on different pharmacological pathways.

Q: Does the size of the TransAct patch correlate with the amount of medicine delivered?

Official product information states that each TransAct patch contains a fixed amount of the active ingredient, 35 mg of flurbiprofen. This fixed dose is the total amount available to be delivered from the transdermal system.

Q: What makes the flurbiprofen in TransAct patches effective locally instead of systemically?

The patch is defined as a Transdermal Therapeutic System specifically formulated with a polymer matrix. This design ensures the drug concentrates in the affected localized tissue for targeted relief, rather than aiming for high systemic absorption.

Q: Do I need a prescription to buy TransAct patches?

The regulatory classification for TransAct varies by country. In some regulatory territories, the medicine is classified with a non-prescription status and may be available for over-the-counter supply.

Q: Is TransAct safe to use while operating heavy machinery or driving?

Official labeling documents note that systemic effects, such as slight dizziness or other nervous system effects, are possible. These types of effects may potentially impair the ability to operate machinery or vehicles.

How should TransAct be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define specific conditions for storing and disposing of TransAct (Flurbiprofen patch) to maintain its stability and ensure safety. These are non-advisory, official labeled requirements.

Condition	Requirement
Temperature	Store at or below 25 C.
Prohibited Storage	Do not refrigerate and do not freeze the patches.
Packaging	Reseal the original sachet immediately after removing a patch.
In-Use Stability	The product must be used no longer than one month after the sachet is initially opened.
Safety	Keep TransAct patches out of the reach of children.
Disposal	Unused or expired patches and waste material must be disposed of in accordance with local regulations; check with a pharmacy for specific guidance.

TransAct